116419-94-4Relevant articles and documents
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)
Lu, Tingting,Cao, Jiangyan,Zou, Fengming,Li, Xixiang,Wang, Aoli,Wang, Wenliang,Liang, Huamin,Liu, Qingwang,Hu, Chen,Chen, Cheng,Hu, Zhenquan,Wang, Wenchao,Li, Lili,Ge, Jian,Shen, Yang,Ren, Tao,Liu, Jing,Xia, Ruixiang,Liu, Qingsong
, (2021)
As the critical driving force for chronic myeloid leukemia (CML), BCR gene fused ABL kinase has been extensively explored as a validated target of drug discovery. Although imatinib has achieved tremendous success as the first-line treatment for CML, the l
Spiro derivative, preparation method thereof and application of spiro derivative in medicine
-
Paragraph 0484-0489, (2021/08/19)
The invention relates to a spiro derivative, a preparation method thereof and application of the spiro derivative in medicine. Specifically, the invention relates to the spiro derivative shown in a general formula (I), the preparation method thereof, a pharmaceutical composition containing the spiro derivative and application of the spiro derivative as a therapeutic agent, especially application of the spiro derivative as an RAF inhibitor and application of the spiro derivative in preparation of drugs for treating or preventing various diseases (including cancers) related to over-expression RAF activity.
A novel structure of the kinase inhibitors
-
Paragraph 0101; 0107; 0108, (2018/06/07)
The invention provides compounds of a novel kinase inhibitor as shown in the formula (I) or pharmaceutically acceptable salts, solvates, esters, acids, metabolites, combination drugs or prodrugs thereof. The compounds independently combines with at least
